Race Oncology EMD AML Trial Featured on NBN News
Race Oncology Investor Briefing – Melbourne 20th Oct 2022
Pitt St Research interview with Race Oncology’s CEO Phil Lynch & CSO Dr Daniel Tillett
Race Oncology June 2022 Quarterly Investor Briefing
Race Oncology June 2022 Quarterly Investor Briefing
Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session....
Race Oncology Presents at the Gold Coast Investor Showcase 2022
Race CMO Dr David Fuller Talks to Proactive about latest Zantrene Trial News
Cancer Drug Trial
Cancer Drug Trial
Race Oncology CSO Dr Daniel Tillett talks to WIN Television News about Race Oncology’s research collaboration with the University of Wollongong....
